assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 100 mg (860547P-100mg), pkg of 1 × 25 mg (860547P-25mg), pkg of 1 × 5 mg (860547P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
lipid type
sphingolipids
shipped in
dry ice
storage temp.
−20°C
SMILES string
[H][C@](/C=C/CCCCCCCCCCCCC)(O)[C@@]([H])(NC(CCCCCCCCCCCCCCCCC)=O)CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O
InChI
1S/C42H81NO8/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-38(46)43-35(34-50-42-41(49)40(48)39(47)37(33-44)51-42)36(45)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h29,31,35-37,39-42,44-45,47-49H,3-28,30,32-34H2,1-2H3,(H,43,46)/b31-29+/t35-,36+,37?,39+,40?,41?,42+/m0/s1
InChI key
YMYQEDCYNANIPI-KNSMPFANSA-N
Application
C18 Glucosyl(β) Ceramide (d18:1/18:0) or D-glucosyl-β-1,1′-N-stearoyl-D-erythro-sphingosine has been used:
- as a lipid standard for its quantification using differential ion mobility spectrometry (DMS) coupled with liquid chromatography in electrospray ionization tandem mass spectrometry (LC-ESI-DMS-MS/MS) in human plasma
- in the preparation of lipid dispersions
- used in an assay to monitor the turnover of glucosylceramide in glucocerebrosidase (GBA1) cell free system
Packaging
5 mL Amber Glass Screw Cap Vial (860547P-100mg)
5 mL Amber Glass Screw Cap Vial (860547P-25mg)
5 mL Amber Glass Screw Cap Vial (860547P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
存储类别
11 - Combustible Solids
法规信息
涉药品监管产品
此项目有
Jong Hoon Won et al.
Neuroscience, 427, 1-15 (2019-11-26)
Neurotransmitter release is mediated by ceramide, which is generated by sphingomyelin hydrolysis. In the present study, we examined whether synaptosomal-associated protein 25 (SNAP-25) is involved in ceramide production and exocytosis. Neutral sphingomyelinase 2 (nSMase2) was partially purified from bovine brain
Hongbin Xu et al.
Journal of lipid research, 60(1), 200-211 (2018-11-11)
Cerebrosides, including glucosylceramides (GlcCers) and galactosylceramides (GalCers), are important membrane components of animal cells with deficiencies resulting in devastating lysosomal storage disorders. Their quantification is essential for disease diagnosis and a better understanding of disease mechanisms. The simultaneous quantification of
Victoria Schiffer et al.
PloS one, 15(1), e0227077-e0227077 (2020-01-14)
Gaucher disease is caused by a deficiency in glucocerebrosidase that can result in non-neuronal as well as neuronal symptoms. Common visceral symptoms are an increased organ size, specifically of the spleen, and glucosylceramide as well as glucosylsphingosine substrate accumulations as
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 860547P-100MG | 04061835318063 |
| 860547P-5MG | 04061835318087 |